摘要
【目的】探讨半乳糖凝集素-3(Galectin-3 Gal-3)和β-Catenin在上皮性卵巢癌组织中的表达情况及临床意义。【方法】采用免疫组织化学方法,检测77例上皮性卵巢癌患者肿瘤组织中Gal-3和β-Catenin蛋白表达的情况,并分析其与患者临床病理特征、治疗效果及预后的关系。【结果】在77例卵巢癌组织中,Gal-3阳性表达率为(70/77)90.9%。β-catenin阳性表达率为(65/77)84.4%。正常卵巢上皮不表达Gal-3和β-Catenin蛋白。Gal-3和β-Catenin的表达常表现为正相关关系,相关系数r=0.437,P=0.000。将弱阳性与强阳性合并为阳性后进行统计分析,Gal-3与病理类型相关,β-Catenin与病理类型、是否复发相关,P<0.05。单因素(Cox回归)分析显示,临床分期(P=0.019)、复发(P=0.007)、铂耐药(P=0.000)及Gal-3表达(P=0.007)为影响上皮性卵巢癌患者术后总体生存(OS)的因素。多因素分析显示,铂类耐药(HR=0.233,P=0.001)与Gal-3表达(HR=2.325,P=0.036)与预后明显相关。【结论】Gal-3和β-Catenin可能与上皮性卵巢癌的发生发展有关,并可作为上皮性卵巢癌预后不良的预测指标,Gal-3可能通过β-Catenin激活经典的Wnt通路,在在上皮性卵巢癌中,发生、发展中起重要作用。
【Objective】 To evaluate the expression of galectin-3 and β-catenin in epithelial ovarian cancer tissues and their correlation with clinicopathological and survival variables. 【Method】 Seventy-seven patients with epithelial ovarian cancers（EOC）were selected, and their tumor tissues were collected. The expression of galectin-3 and β-catenin were tested by immunohistochemical analysis. Then the correlation of the expression of Gal-3 and β-catenin with the clinicopathological parameters, treatment outcomes and survival of these patients were evaluated. 【Result】 Galectin-3 protein, which was mainly cytoplasmic in location, was observed in a majority（70 / 77, 90.9%） of the EOC but not in normal ovarian tissues（P〈0.05）. β-Catenin protein, which was mainly cytoplasmic and membranous in location, was observed in a majority（65 / 77, 84.4%） of the EOC but not in normal ovarian tissues（P〈0.05）. Combine weak staining with strong staining, Gal-3 expression in EOC correlated with histology, while β-Catenin expression correlated with histology and recurrence. Spearman bivariate correlation test show a positive correlation between the expression of Gal-3 and β-Catenin in EOC,r = 0.437,P = 0.000. Univariate analysis revealed that stage（P = 0.019）, recurrence（P =0.007）, platinum resistance（P = 0.000） and high Gal-3 expression（P = 0.007） predicted overall survival（OS）. Further multivariate analysis showed platinum resistance（HR = 0.233 P = 0.001）and Gal-3 expression（HR = 2.325, P = 0.036）was independent prognostic factor for OS for these patients. 【Conclusions】 Gal-3 may activate Wnt pathway by mediate β-Catenin in the cytoplasm in EOC.Gal-3 may become a prognosis factor of recurrence, platinum resistance and poor outcome. New drugs which targeting Gal-3 are expected to become effective therapies for platinum-resistant EOC.
出处
《中山大学学报（医学科学版）》
CAS
CSCD
北大核心
2015年第6期883-888,共6页
Journal of Sun Yat-Sen University:Medical Sciences
基金
广东省自然科学基金重点项目(S2012020010913)
作者简介
卢淮武，在职博士，主治医师，研究方向：妇科肿瘤，E-mail：luhuaiwu@163．com；
林仲秋，通信作者，E-mail：lin-zhongqiu@163.com
